Now that Alnylam Pharmaceuticals Inc’s volume has hit 0.75 million, investors get a glimpse of its size.

On Friday, Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) was -3.19% drop from the session before settling in for the closing price of $264.89. A 52-week range for ALNY has been $141.98 – $304.39.

A company in the Healthcare sector has jumped its sales by 63.53% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 22.44%. With a float of $123.92 million, this company’s outstanding shares have now reached $129.29 million.

In an organization with 2230 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 85.62%, operating margin of -7.87%, and the pretax margin is -16.79%.

Alnylam Pharmaceuticals Inc (ALNY) Insider Updates

Also, it is sometimes useful to examine the sentiment of large-scale investors toward Alnylam Pharmaceuticals Inc stocks. The insider ownership of Alnylam Pharmaceuticals Inc is 4.26%, while institutional ownership is 95.36%. The most recent insider transaction that took place on Jan 27 ’25, was worth 14,988,720. In this transaction CMO & EVP Dev & Med Affairs of this company sold 52,592 shares at a rate of $285.00, taking the stock ownership to the 11,989 shares. Before that another transaction happened on Jan 27 ’25, when Company’s Officer proposed sale 52,592 for $285.00, making the entire transaction worth $14,988,720.

Alnylam Pharmaceuticals Inc (ALNY) Performance Highlights and Predictions

Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.25 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 22.44% per share during the next fiscal year.

Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) Trading Performance Indicators

You can see what Alnylam Pharmaceuticals Inc (ALNY) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 2.71. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 14.77.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.17, a number that is poised to hit -0.94 in the next quarter and is forecasted to reach 0.82 in one year’s time.

Technical Analysis of Alnylam Pharmaceuticals Inc (ALNY)

Let’s dig in a bit further. During the last 5-days, its volume was 0.7 million. That was better than the volume of 0.68 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 25.80%. Additionally, its Average True Range was 9.36.

During the past 100 days, Alnylam Pharmaceuticals Inc’s (ALNY) raw stochastic average was set at 35.68%, which indicates a significant increase from 14.45% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 22.97% in the past 14 days, which was lower than the 37.64% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $255.02, while its 200-day Moving Average is $240.74. However, in the short run, Alnylam Pharmaceuticals Inc’s stock first resistance to watch stands at $263.59. Second resistance stands at $270.73. The third major resistance level sits at $276.59. If the price goes on to break the first support level at $250.59, it is likely to go to the next support level at $244.73. Assuming the price breaks the second support level, the third support level stands at $237.59.

Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) Key Stats

There are 128,981K outstanding shares of the company, which has a market capitalization of 33.20 billion. As of now, sales total 1,828 M while income totals -440,240 K. Its latest quarter income was 500,920 K while its last quarter net income were -111,570 K.